Skip directly to content

2017 Publications

HIV Cure Information Sheet
December 14, 2017 – A TAG information sheet on the current state of research into curing HIV infection.

TAGline 2017

December, 2017 – TAG's progress on the fight to end HIV/AIDS, viral hepatitis, and tuberculosis.

The Ascent Begins: Tuberculosis Research Funding Trends, 2005-2016
November 8, 2017 – The world spent $726 million on tuberculosis (TB) research in 2016, marking the first time annual spending has exceeded $700 million since TAG began tracking funding in 2005. Although this figure is $105 million above 2015 levels, it remains woefully inadequate when judged against the innovation gaps holding back the TB response and the ambitious global goals to end the TB epidemic by 2030.

End the Epidemic Resources: Southern States EtE Meeting Summary and FAQs
November 2, 2017 – One thing is abundantly clear: We can’t end the epidemic in the U.S. if we don’t end it in the South. In May, TAG, the Southern AIDS Coalition, the Southern HIV/AIDS Strategy Initiative, Sisterlove, AIDS Alabama, and the National Alliance of State and Territorial AIDS Directors (NASTAD) held a consultation with more than 40 community advocates and key stakeholders from across the Deep South to assess the major challenges and opportunities for EtE planning. Several key findings from that meeting can be found in a summary report.

HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials
September 27, 2017 – The effectiveness of pre-exposure prophylaxis (PrEP) with the antiretroviral drug combination TDF/FTC (Truvada) raises questions regarding the design and conduct of trials of other candidate biomedical HIV prevention interventions, such as vaccines, passive immunization and alternative forms of PrEP.

An Activists Guide to the TB LAM Test
September 11, 2017 – As tuberculosis (TB) has risen to become the leading infectious killer of people living with HIV (PLHIV), diagnostic tests such as the TB LAM test are critically important to ensure diagnosis of TB quickly for this vulnerable population. An Activist's Guide to the TB LAM Test provides important messaging and strategies to support in-country LAM advocacy and activism.

2017 Pipeline Report: Promising New HIV, TB & HCV Drugs and Diagnostics
July 18, 2017 – Our annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

2016 Annual Report
June 14, 2017 – Today more than ever, TAG’s work is vital. TAG’s passionately dedicated, deeply informed staff have been unstinting in their efforts to speed up research and high-quality prevention, treatment, and care programs for people living with HIV, hepatitis C virus (HCV), or tuberculosis (TB), and for those most at risk of acquiring these infections.

An Activist's Protocol Review Toolkit  
May 2017 – An Activist's Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols. The three tools contained in the toolkit will help Community Advisory Boards (CABs) think through different aspects of trial design and implementation, organize feedback for the research team, and evaluate impact on study design and implementation.

HIV Activist Learning Modules: Engaging our Community in HIV Prevention Policy Advocacy
March 29, 2017 – To support the efforts of prevention advocates across the United States, TAG's HIV Project has developed a series of modules to help support activists’ capacity needs and to develop advocacy action plans. The slides, handouts, and webinars in each of the four modules focus on how to identify and change the governmental, organizational, and institutional policies that create roadblocks to comprehensive HIV prevention in our communities. The materials are useful for personal education or group discussion on HIV prevention and policy advocacy.

No Time to Lose: G20 Leadership in  TB Research Needed to End TB
​March 2017--Tuberculosis (TB) is the leading infectious cause of death, and drug-resistant forms of TB account for one in three deaths from antimicrobial resistance. TB research has received scant resources, limiting the possibility of developing the new diagnostic, treatment, and prevention options urgently needed to end TB. In this brief, TAG challenges G20 member states to collectively spend $5.8 billion on TB research and development between 2016 and 2020.

An Activist’s Guide to Tuberculosis Diagnostic Tools
February 2017 - Understanding tuberculosis (TB) diagnosis is critical to understanding why the world is currently failing to end TB. Nearly half of people with TB—over 4 million per year—are undiagnosed, leaving them ill and at risk of death and with the potential to transmit disease to others.  Closing this massive gap will require much better use of the current diagnostic methods, as well as research into faster, simpler, more accurate, and less expensive options.

An Activist’s Guide to Tuberculosis Diagnostic Tools provides an overview of the different tests and strategies for detecting TB, including their benefits and limitations. The guide also makes recommendations for how activists and clinicians can contribute to improved TB diagnosis.

Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas
January 9, 2017 – New Report Shines Spotlight on Need for More Investments in Community Leadership and Mobilization to End HIV as an Epidemic